CPCML patients with deep and sustained molecular responses were able to remain treatment-free without facing a molecular relapse in approximately 50% of the cases.4 While achievement and maintenance of MMR on-therapy remains an essential step during CML patient management, obtaining a deep molecular...
Currently, five TKIs (imatinib, dasatinib, nilotinib, bosutinib and ponatinib) are approved for the treatment of CML and can be used as first, second or further lines of treatment according to disease risk scores, patient comorbidities and the presence of known TKI resistance mechanisms. In fact...
Judy Orem now represents CML patients in meetings with the Food and Drug Administration. WhileMortensenis the longest living CML survivor, Orem is the longest surviving patient continuously on Gleevec. Can you live a long life with CML? Improvements in treatment, such as the introduction of tyrosi...
14 Therefore, in a patient like ours it is important to aggressively control all risk factors. This includes properly managing underlying conditions such as hypertension and making the lifestyle changes necessary to decrease risk (eg, stop smoking, lose weight, exercise). Aspirin is sometimes ...
[CML] Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemiaRob [CML] Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.Rob ...
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML ...
[28]. Conversely, allogeneic tumor cell lysates, could supply a wider variety of tumor antigens and elicit a strong immune response as effective antigen sources [29]. The application of tumor cell lysates is more conducive to personalized treatment even if a patient’s tumor mutates. Therefore...
A lot of people would assume that there is some sort of immune surveillance that allows a patient to stay in remission. For some people, the leukemia is escaping the immune system. There are upcoming clinical trials with second drugs looking at patients who have stopped treatment, relapsed, ...
The current thinking is that any patient with CML that presents in or develops blast crisis needs HSCT for cure. Although this is not established definitively, it is standard clinical practice.8 We know that many children with Ph+ ALL can be cured without HSCT; in some cases, patients have...
As of the data cutoff date, 11 patients (25.6%) discontinued treatment due to factors including adverse events (3 patients, 7%), treatment failure (2 patients, 4.7%), and disease progression (1 patient, 2.3%). Reference Weiming L, Zhang Y, Zhu H, et al. Olverembatinib as second-line...